Numbers | 184 | 184 | 150 |
Male/female | 46/138 | | |
Disease duration (years) | 12 (0 to 55) | | |
Age at inclusion (years) | 56 (20 to 84) | | |
Previous number of DMARDs | 3 (2 to 5) | | |
Steroid dose (mg/week) | 35 (17 to 57) | 35 (0 to 53)* | 18 (0 to 35)* |
ESR (mm/h) | 31.5 (20 to 54) | 20 (12 to 34)* | 20 (10 to 38)* |
C reactive protein (mg/litre) | 21 (10 to 42) | 9 (1 to 22)* | 9 (1 to 23)* |
VAS pain (mm) | 64 (47 to 78) | 34 (16 to 55)* | 29 (15 to 55)* |
VAS global (mm) | 66.5 (49 to 81) | 34 (15 to 55)* | 29 (15 to 57)* |
Physician’s global assessment | 2 (2 to 3) | 1 (1 to 2)* | 1 (1 to 2)* |
28 tender joint count | 7.5 (3 to 13) | 2 (0 to 5.5)* | 2 (0 to 6)* |
28 swollen joint count | 9 (5 to 12) | 3 (1 to 6)* | 3 (0 to 6)* |
HAQ | 1.4 (1 to 1.9) | 1.1 (0.6 to 1.6)* | 1.1 (0.6 to 1.6)* |
DAS 28 | 5.6 (4.7 to 6.4) | 3.8 (2.8 to 4.8)* | 3.7 (2.7 to 4.8)* |
SDAI | 31 (24 to 41) | 14 (9 to 24)* | 13 (7 to 22)* |